LXRX vs. AVEO, RZLT, SRRA, DVAX, LGND, BCRX, MNKD, IRWD, INVA, and OPK
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include AVEO Pharmaceuticals (AVEO), Rezolute (RZLT), Sierra Oncology (SRRA), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), and OPKO Health (OPK). These companies are all part of the "medical" sector.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and AVEO Pharmaceuticals (NASDAQ:AVEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 50.0% of AVEO Pharmaceuticals shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of AVEO Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
AVEO Pharmaceuticals received 1 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 69.76% of users gave AVEO Pharmaceuticals an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
Lexicon Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 194.12%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than AVEO Pharmaceuticals.
In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than AVEO Pharmaceuticals. MarketBeat recorded 4 mentions for Lexicon Pharmaceuticals and 0 mentions for AVEO Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.47 beat AVEO Pharmaceuticals' score of 0.25 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
Lexicon Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
AVEO Pharmaceuticals has a net margin of -30.79% compared to Lexicon Pharmaceuticals' net margin of -8,311.12%. AVEO Pharmaceuticals' return on equity of -81.66% beat Lexicon Pharmaceuticals' return on equity.
AVEO Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. AVEO Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Lexicon Pharmaceuticals beats AVEO Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
